摘要
近年来,新型口服降糖药物钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)在2型糖尿病患者心血管获益方面涌现出大量证据,多项临床试验显示SGLT2i可以显著降低2型糖尿病患者心血管死亡风险和心力衰竭住院率,其中达格列净被证实对非糖尿病的心力衰竭患者同样具有心血管保护作用。目前针对SGLT2i心血管获益机制方面的研究已取得部分进展,本文将从容量调节学说、改善血管内皮功能、改善心肌能量代谢、改善心室重构和调节全身代谢等5个方面阐述SGLT2i心血管获益的机制。
Nowadays,it has emerged a lot of evidences that a new oral hypoglycemic drug sodium-glucose cotransporter 2 inhibitor(SGLT2 i)can acquire cardiovascular benefits in patients with type 2 diabetes.A number of clinical trials have shown that SGLT2 i can significantly reduce the cardiovascular death and hospitalization for heart failure of patients with type 2 diabetes.Dapagliflozin has been proven to have cardiovascular protection for non-diabetic heart failure patients.At present,the research on the cardiovascular benefits mechanisms of SGLT2 i has made some progress.This article reviews the cardiovascular benefits mechanisms of SGLT2 i in five aspects:volume regulation,improvement of vascular endothelial function,amelioration of cardiac energy metabolism,improvement of ventricular remodeling,and regulation of systemic metabolism.
作者
吴岑岑
蔡嘉庚
祖凌云
WU Cen-cen;CAI Jia-geng;ZU Ling-yun(Department of Cardiology and Institute of Vascular Medicine,Peking University Third Hospital,NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides,Key Laboratory of Molecular Cardiovascular Science,Ministry of Education,Beijing Key Laboratory of Cardiovascular Receptors Research,Beijing 100191,China)
出处
《中国心血管病研究》
CAS
2021年第4期350-357,共8页
Chinese Journal of Cardiovascular Research
基金
国家自然科学基金(81670323)
中国心血管联盟进阶基金(2019-CCA-ACCESS-069)
北京大学临床医学+X青年项目(PKU2020LCXQ005)。
